Female subject must agree not to breastfeed at screening and throughout the study period and for 45 days after the final study drug administration. Female subject must not donate ova starting at screening and throughout the study period and for 45 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
Female participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.
Male participants must not donate sperm throughout the study drug treatment period and for 127 days after the final study drug administration.
If of reproductive potential, agrees to use a highly effective from of contraception or avoid intercourse during and upon completion of the study and for at least 4 months after the last dose of study drug, and agrees not to retrieve, freeze or donate sperm or ova starting at Screening and throughout the study period, and at least 4 months after the final study drug administration
Female subject who is of childbearing potential must agree not to breastfeed starting at screening and throughout the study and for 28 days after the final study drug administration.
Female subject who is of childbearing potential must not donate ova starting at screening and throughout the study and for 28 days after the final study drug administration.
Male subject who is of childbearing potential must not donate sperm starting at screening and throughout the study and, for 90 days after the final study drug administration.
Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
Female subject must not donate ova starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and, for 6 months after the final study drug administration Note: *Highly effective forms of birth control include:
Is not breastfeeding at screening and will not breastfeed throughout the study period and for at least 3 months after final drug administration
Must not donate sperm starting at screening throughout the study period and for 90 days after the final study drug administration.
Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study treatment administration.
Female subject must not donate ova starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
Agree to use a male condom starting at screening and continue throughout study treatment and for 6 months after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and for 6 months after the final study drug administration.
Female subject must agree not to breastfeed at Screening and throughout the study period and for 60 days after the final study drug administration.
Female subject must not donate ova starting at Screening and throughout the study period and for 180 days after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and 120 days after the final study drug administration.
In a man whose sexual partner is a woman of childbearing potential, unwillingness or inability of the man or woman to use a highly effective contraceptive method for the entire study treatment period for at least 3 months after study completion. Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and 105 days after the final study drug administration.
Female Subjects must agree to not breastfeed from the time of Screening and throughout the study period, and for 25 days after the final study drug administration.
Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
Female subject must not donate ova starting at Screening and throughout the study period, and for 180 days after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and, for 120 days after the final study drug administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
Female subject must not be breastfeeding at Screening or during the study period and for 3 months after final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and for at least 3 months after final drug administration.
Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration.
Female subject must not donate ova starting at Screening and throughout the study period, and for 180 days after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and for 120 days after the final study drug administration.
Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final study drug administration.
Female subject must not donate ova starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
Female subject must agree not to breastfeed at screening and throughout the study period, and for 28 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period, and for 90 days after the final study drug administration.
Must not donate sperm from screening through 3 months after final study drug administration.
Female subject must not be breastfeeding at screening or during the study period, and for 60 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period and for 60 days after final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after final study drug administration.
Female subject must not be breastfeeding at screening or during the study period, and for 28 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration. *Acceptable forms of birth control include:
Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 4 months and 1 week after the final study drug administration.
